Pharma BD Deal Intelligence
BMS / Inhibitex: Failed to Achieve (Score: 26/100)
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
BMS acquired Inhibitex for $2.5B for hepatitis C drug development.
Bristol-Myers Squibb completed its acquisition of Inhibitex, Inc. for $26.00 per share in cash through a tender offer, acquiring the hepatitis C drug developer…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
BMS acquired Inhibitex for $2.5B for hepatitis C drug development.
BMS / Inhibitex: Failed to Achieve (Score: 26/100)
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Inhibitex Inc. (this deal) | 2012 | $2.5B | 8 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2012 deals · Bristol-Myers Squibb Company deals · Infectious Disease deals